engleski

Feasibility of obinutuzumab (G) combined with higher doses of chlorambucil (Clb) for frontline treatment of CLL: a retrospective non-interventional study of KroHem, the Croatian Cooperative Group for Hematologic Diseases

Prolonged steroid premedication and/or reduction of lymphocyte count with Clb prior to administering first dose of G might result in a lower frequency of severe infusion reactions observed in our series In contrast to rituximab, the combination of G with higher-doses of Clb frequently results in premature stopping of the latter, especially in patients with serious comorbidities. This prevents the delivery of the intended total dose of Clb and reduces the possibility to improve efficacy over G þ Clb pulses.

KroHem ; obinutuzumab (G) ; chlorambucil (Clb)

nije evidentirano